On March 27th, Wuxi WuXi PharmaTech New Drug Development Co., Ltd. (hereinafter referred to as “Guo Ming Kang Deâ€), which launched an impact on A shares, successfully attended the 51st working meeting of the Audit Committee. It should be noted that it took only 50 days from the pre-disclosure of the prospectus of WuXi PharmaTech to be successful.
According to the prospectus, WuXi PharmaTech's main business is the comprehensive, integrated platform service for the discovery, research and development and production of small molecule chemical drugs, as well as a small number of other services such as macromolecular biopharmaceutical business and medical health technology services; The largest and most global small-scale pharmaceutical R&D service company, known as the “Huawei†in the pharmaceutical industry.
WuXi PharmaTech plans to publicly issue no more than 104 million shares, and the proceeds from the issuance of funds will be deducted from the Suzhou Drug Safety Evaluation Center, Tianjin Chemical R&D Laboratory expansion and upgrade, and antibody-coupled drugs (ADCs) intermediates. And 10 projects including the development and application of digital imaging imaging drugs/reagent carriers; the total investment was about 5.741 billion yuan.
According to financial data, in 2014-2016 and January-September 2017, WuXi PharmaTech's operating income was approximately 4.14 billion yuan, 4.883 billion yuan, 6.116 billion yuan and 5.678 billion yuan respectively; The net profit attributable to the vesting was approximately 462 million yuan, 349 million yuan, 975 million yuan and 1.063 billion yuan.
It is reported that WuXi PharmaTech is a joint stock limited company established by Pharma-Ming limited overall change. On March 1, 2017, the company registered industrial and commercial registration in Wuxi City Administration for Industry and Commerce, obtained business license, and registered capital of approximately 938 million yuan. The legal representative is Ge Li (Li Ge). WuXi PharmaTech has no controlling shareholder, Ge Li (Li Ge) and Ning Zhao (Zhao Ning), Liu Xiaozhong, and Zhang Zhaohui are the founders of WuXi PharmaTech. By signing the agreement on concerted action, the above four are the actual controllers of WuXi PharmaTech. Co-control of WuXi PharmaTech's total voting rights of 34.4812%.
The prospectus disclosed by WuXi PharmaTech shows that WuXi Cayman (Wuxi Cayman), the original indirect controlling shareholder of the company, was listed on the NYSE on August 9, 2007, and completed the NYSE on December 10, 2015. City process. WuXi Cayman (Wuxi Cayman) is a listed company that was established in the United States for the realization of Yaoming Limited (predecessor of WuXi PharmaTech). The only shareholder and actual controller at the time of its establishment were Ge Li (Li Ge). In the eyes of the industry, WuXi PharmaTech's 50-day "Lightning" has passed or the IPO of the company has returned to A. (Beijing Business Daily Cui Qibin Ma exchange)
Concentrated extraction powder is a plant as raw material, in accordance with the need for the use of the extracted end product, after physicochemical extraction and separation process, directed to obtain and concentrate one or more of the active ingredients in the plant, without changing the structure of its active ingredients and the formation of the product. According to the extraction of plant components, the formation of glycosides, acids, polyphenols, polysaccharides, terpenes, flavonoids, alkaloids, etc.; according to the different traits, can be divided into plant oils, extracts, powders, crystals and so on.
Concentrated Extract Powder,Proportional Extract,Extractum,Concentrated Powder
Shaanxi Zhongyi Kangjian Biotechnology Co.,Ltd , https://www.zhongyibiology.com